Moebius Medical Ltd. products

Moebius’s lead product, MM-II, is a novel non-opioid intra-articular injection that leverages the physical properties of proprietary multilamellar liposomes and an innovative mechanism-of-action to provide sustainable relief of symptomatic knee pain in osteoarthritic patients. Extensive pre-clinical work has demonstrated MM-II’s safety and lubricating properties, which work to reduce joint friction and wear of cartilage, and a first-in-human study has demonstrated MM-II’s tolerability and ability to reduce knee pain in OA patients. The clinical development of MM-II is continuing in collaboration with Sun Pharmaceuticals, and we are currently enrolling patients in a large dose-ranging clinical trial in the US, Denmark and Hong Kong.